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Introduction
The acute and chronic loss of renal function are interrelated 
syndromes with a rising incidence as well as poor treatment 
outcomes and high-related costs. Acute kidney injury (AKI) 
is characterized by a rapid decline of renal function and 
associates with an increase of mortality and hospitalization. 
In fact, AKI is a common complication in hospitalized 
patients with acute illness thus having great impact on public 
health resources (1). Moreover, 8% to 16% of patients 
with AKI develop chronic renal failure (2). Chronic kidney 
disease (CKD) may progress to end-stage renal disease 
(ESRD), resulting from a maladaptive response to injury, 
with fibrosis and progressive loss of function. In developed 
countries, diabetic nephropathy (DN) is one of the main 
causes of ESRD due to escalation in the frequency of 
obesity and diabetes (3). The main therapies for loss of renal 
function include dialysis and kidney transplantation (4). 
None of them is satisfactory and the increase of survival 
rate after therapies is not adequate. While hemodialysis 
has high cost and elevated complications, the number of 
compatible kidney organs is not enough to satisfy the organ 
need (5). For these reasons, there is an urgent need to find 
new effective therapeutic strategies. 
In the last decades, many reports demonstrated the 
improvement of renal dysfunction by the administration 
of stem cells (4). In particular, mesenchymal stromal 
cells (MSCs) have been extensively used in experimental 
models of kidney injury (6) as well as in clinical trials 
(4,7). The described mechanism of action is mainly due 
to the release of trophic factors including growth factors, 
cytokines and extracellular vesicles (EVs), favoring 
tissue repair and reducing inflammation (8). Recently, 
literature data highlight the use of stem cell-derived 
EVs per se as innovative option, alternative to cell based 
strategies, to treat renal failure in pre-clinical models (9). 
In fact, EVs released by different types of stem cells 
are described to ameliorate AKI and to prevent chronic 
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progression in several preclinical experimental models 
(Tables 1 and 2) (34). EVs may influence different cell types 
acting on physiological processes such as proliferation (35), 
angiogenesis (36) and immune escape (9). In the present 
review, we intend to offer an update on the pre-clinical 
models used to test EVs in prevention and treatment of 
renal injury, as well as in pre-transplant conditioning, and 
on the mechanisms involved (Figure 1).
Stem cell EVs and AKI
EVs are a heterogeneous population of double layers 
membrane fragments, differing for size, sedimentation rate 
and floating density (37,38). They are released by most of 
cell types and contain several biologically active molecules 
such as proteins, lipids and nucleic acids (mRNAs and non-
coding RNAs such as miRNAs and other small RNAs) (39). 
EVs may influence recipient cells by various mechanisms 
such as surface receptor interaction, direct stimulation or 
by transfer of proteins and/or genetic material (40-43). 
Due to the common characteristics and pro-regenerative 
potential of MSCs of several organs, MSC-derived EVs of 
different origin have been tested in preclinical models (44). 
In particular, EVs have been obtained from bone marrow 
MSCs (BM-MSCs), from adipose derived MSCs (ASCs) and 
from fetal MSCs: cord blood (CB) and Warthon’s Jelly (WJ), 
as well as from resident MSCs isolated from renal or liver 
tissues (45,46). Recently, MSCs from urine were also isolated 
and applied in experimental models of renal injury (47). 
MSC-EVs and AKI
The most common feature of AKI is the rapid loss of renal 
tubular cells with a decrease of renal function and increase 
Table 1 EVs of different origin in animal models of AKI
Cell sources of EVs In vivo models of renal injury Doses Administration Efficacy References
BM-MSCs Glycerol Single injection: 15 µg; 2.2×10
8
 EV Intravenously Y (10,11)
IRI Single injection: 30 µg Intravenously Y (12)
Cisplatin Single injection: 100 µg Intravenously Y (13)
Gentamicin Multiple injections: 100 µg Intravenously Y (14)
IRI Single injection: 200 µg Into renal capsule Y (15)
CB-MSCs Cisplatin Single injection: 200 µg Caudal vein Y (16)
IRI Single injection: 30 µg Caudal vein Y (17)
WJ-MSCs IRI Single injection: 100 µg Caudal vein Y (18)
Caudal vein Y (19)
K-MSCs IRI Single injection: 2×10
7
Intravenously Y (20)
IRI Single injection: 400×10
6
Intravenously Y (21)
L-MSC (HLSC) Glycerol Single injection: (1.88±0.6)×10
9
Intravenously Y (22)
Single injection: (5.53±2.1)×10
9
Intravenously Y
EPCs IRI Single injection: 30 µg Intravenously Y (23)
Thy1.1 glomerulonephritis Single injection: 30 µg Intravenously Y (24)
ECFCs IRI Single injection: 15 µg Right jugular vein Y (25)
Single injection:
20 µg
Right jugular vein Y (26)
ASCs Cisplatin Double injections: 100 µg Intravenously Y (27)
EVs released by different stem cell type are effective in models of AKI. Cells of EV origin, animal models, doses, route of administration 
and efficacy are listed. AKI, acute kidney injury; BM, bone marrow; CB, cord blood; WJ, Warthon’s Jelly; K, kidney; L, liver; EPC, 
endothelial progenitor cell; ECFC, endothelial colony-forming cells; ASC, adipose stromal cells; Y, yes.
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Table 2 EVs of different origin in animal models of CKD
Cell sources of 
EVs
In vivo models of renal injury Doses Administration Efficacy References
BM-MSCs IRI Single injection: 30 µg Intravenously Y (12)
Cisplatin Multiple injections: 100 µg followed by 50 µg 
every 4 days
Intravenously Y (13)
Remnant kidney Single injection: 30 µg Caudal vein Y (28)
Diabetic nephropathy induced by 
streptozotocin
Single injection: 5.3×10
7
 exosomes Renal subcapsular Y (29)
Unilateral ureteral obstruction Single injection: 30 µg MV Caudal vein Y (30)
EPCs IRI Single injection: 30 µg Intravenously Y (23)
Urine derived 
MSCs
Diabetic nephropathy induced by 
streptozotocin
Multiple injections: 100 µg weekly (12 times) Intravenously Y (31)
Embryonic 
derived MSCs
Remnant kidney and specific diet 
(L-N
G
-nitroarginine and 6% NaCl)
Multiple injections: 7 µg twice daily for 4 
consecutive days
Intravenously N (32)
ASCs Porcine model of metabolic 
syndrome and renal artery stenosis
Single injection: 1×10
10
 cells Intra renal Y (33)
EVs released by different stem cell type have been tested in models of CKD. Cells of EV origin, animal models, doses, route of 
administration and efficacy are reported. CKD, chronic kidney disease; BM, bone marrow; EPC, endothelial progenitor cells; ASC, adipose 
stromal cells; IRI, ischemia/reperfusion injury; Y, yes; N, no.
Figure 1 EV treatment in renal injury. Possible EV strategies in AKI, CKD and kidney pre-transplant conditioning. EV, extracellular 
vesicle; AKI, acute kidney injury; CKD, chronic kidney disease; DCD, donation after circulatory death; GFR, glomerular filtration rate.
AKI
GFR
CKD
DCDEV multiple injections
EV single injection
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in retention markers such as blood urea nitrogen and 
creatinine (48). There are different experimental models to 
mimic AKI in animals, performed preferentially in rodents. 
The triggering event may be a toxic compound, an ischemic 
insult or a metabolic dysfunction (7). 
The first evidence of the beneficial effect of EVs shed 
by BM-MSCs was proved by Bruno et al. in 2009 (10), 
in a model of AKI induced by glycerol injection in SCID 
mice. In this model, intramuscle injection of glycerol 
causes rhabdomyolysis, with a detrimental effect on kidney 
function that picks between day 1 and 3 post injection 
(10,49). The authors showed that a single intravenous 
administration of EVs at the peak of damage accelerated 
morphological and functional recovery (10). The effect of 
EVs was superimposable to that induced by the originating 
MSCs suggesting that EVs may substitute cell treatment. 
Moreover, EVs purified by a liver resident MSCs (HLSCs) 
were intravenously administered in the AKI model 
induced by glycerol and improved renal functionality and 
morphology (22).
BM-MSC EVs were also tested in AKI lethal models 
induced by toxic drugs. The cisplatin nephropathy is a 
lethal or sub-lethal model of AKI, depending on the dose 
used, characterized by a rapid loss of renal function with 
a pick 4 days post drug treatment (50,51). A single EV 
administration increased the survival of SCID mice (13). 
In the same model, EVs obtained by CB-MSCs resulted 
effective by protecting from oxidative stress, stimulating 
cell proliferation and reducing cell apoptosis (16). Similarly, 
EV derived from BM-MSCs abated renal dysfunction in 
an AKI model caused by gentamycin injection (14). In all 
toxic models, EVs reduced the renal histological lesions 
such as presence of luminal cell debris and tubular hyaline 
casts as well as necrosis of proximal and distal tubular cells 
(13,14,16). 
Another common feature of different types of AKI 
is hypoxia, frequently associated with oxidative stress 
response (52). Ischemia/reperfusion injury (IRI) model, 
used to mimic hypoxic insult, is usually obtained by a renal 
artery and vein occlusion of one or both kidneys, followed 
by the reestablishment of oxygen supply (53). In order to 
evaluate whether EVs could be effective on the protection 
by ischemic damage, EVs were administered intravenously 
immediately after the transitory deficiency of the blood 
flow in rats (12,17-19). EVs released by BM-MSCs resulted 
effective (12). The same positive effect was obtained using 
EVs released by MSCs derived from fetal tissues such as 
CB-MSCs (17) and by WJ-MSCs (18,19) with different 
mechanisms of action. The injection of EVs shed by CB-
MSCs accelerated tubular cells dedifferentiation and 
growth via rat HGF induction and human HGF transfer. 
On the contrary, EVs released by WJ-MSCs have been 
described to be able to stimulate proliferation and to reduce 
inflammation and apoptosis via mitochondrial protection 
(18,19). Moreover, in a murine model of IRI, BM-MSC 
EVs were injected under the renal capsule resulting effective 
mainly by suppressing inflammation (15). In addition, the 
effect of EVs released by renal MSCs were also investigated 
(20,21). Ranghino et al. demonstrated that MSCs isolated 
from glomeruli and their EVs recovered kidney function 
and reduced ischemic damage stimulating tubular cell 
proliferation (21). In the same model, the administration 
of a population of a resident intratubular CD133 positive, 
with characteristics of progenitor cells, contributed to renal 
recovery (54). However, no effect was observed by use of 
the CD133 positive cell-derived EVs (21). In addition, it 
has been shown that EVs released by mouse renal MSCs 
cultured under hypoxia were able to stimulate angiogenesis 
in vitro and to improve peritubular microvascular rarefaction 
in vivo (20). 
Altogether, these data indicate a potent effect of single 
EV-MSC administration obtained from different sources in 
all models of AKI tested (Table 1). The mechanisms appear 
multiple, promoting proliferation and survival of resident 
cells and limiting inflammation, oxidation and vessel 
rarefaction.
Endothelial progenitor-derived EVs and AKI
Human endothelial progenitors cells (EPCs) are a 
population of progenitors with strong angiogenic ability 
that circulate in peripheral blood and characterized by the 
expression of a variety of vascular surface markers. The 
EVs (EPC EVs) released by EPC isolated from healthy 
subjects have been tested as pro regenerative factors to 
improve renal function. In particular, injection of EPC EVs 
immediately after IRI prevented renal functional injury (23) 
by stimulation of tubular cell proliferation, reduction 
of inflammation and apoptosis (23). In addition, EPC 
EVs resulted effective in a rat model that mimics human 
mesangial proliferative glomerulonephritis obtained by 
intravenous injection of anti-Thy1.1 antibody. Treatment 
with EPC EVs reduced proteinuria, mesangial cells damage 
and glomerular infiltration of inflammatory cells, improving 
renal functionality (24). EVs have been also purified by an 
alternative source of pro-angiogenic endothelial colony-
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forming cells (ECFCs). ECFCs derive from human 
umbilical CB and are endothelial precursors with high 
angiogenic and proliferative capacities (25). The efficacy 
of ECFC EVs was tested in an AKI model induced by 
IRI resulting in the inhibition of macrophage infiltration, 
oxidative stress and tubular necrosis (25). The same group 
better investigated the key factors contained within EVs 
responsible for the beneficial effect (26). They showed 
that miR-486-5p carried by EVs was transferred to renal 
injured tissue, decreasing PTEN and activating AKT with a 
reduction of the ischemic injury (26).
Effect of EV subpopulations in AKI
Strategies used to isolate EVs from cell supernatants 
include polymer-based methods,  gel-permeat ion 
chromatography, membrane filtration, affinity capture, 
density-gradient centrifugations and ultracentrifugation. 
Among the heterogenic EV populations, a special 
effort was dedicated to identify the active fraction/s in 
the promotion of kidney regeneration. Regardless the 
protocol adopted to isolate EVs, the main result consists 
on separation by size or density into the two EV main 
fractions: exosomes and microvesicles. These two fractions 
are distinct by site of generation and size. Exosomes are 
released from multivesicular intracellular bodies with a 
smaller size (around 30–100 nm), while microvesicles 
derive from cell surface budding and have a size up to 500 
nm (37). Furthermore, the use of gradient floating allows 
separating in a major number of EV fractions based on their 
density. Recently Collino et al. by discontinuous density 
gradient separation analyzed three BM-MSC EV fractions 
characterized by the differential expression of typical 
exosomal markers. These fractions showed differential pro-
proliferative and anti-apoptotic capabilities in vitro (55). 
For example, murine monocrotaline pulmonary 
hypertension model treated with MSC-derived exosomes 
prevented and reversed pulmonary hypertensive changes 
typical of the damage. Conversely the treatment with MSC-
derived microvesicles was not able to protect from the 
pulmonary hypertension, underling the different functional 
properties of the two EV types (56).
The functional difference between EV fractions has been 
also studied in in vivo AKI models (9). Recently, Bruno et al. 
showed how BM-MSC exosomes obtained by differential 
ultracentrifugation clearly improved renal function and 
morphology in a murine glycerol-AKI model, comparable 
to total EVs. On the contrary, the microvesicles were not 
able to induce the same positive effect (57). Accordingly, 
Burger et al. demonstrated that exosomes and microvesicles 
isolated by ultracentrifugation from ECFCs promoted a 
different effect on IRI induced endothelial cell injury. Only 
the treatment with ECFC-conditioned media or exosomes 
completely blocked apoptosis, while the microvesicles were 
ineffective. The same result was observed in murine model 
of AKI induced by IRI where the treatment with ECFC-
derived exosomes significantly attenuated renal injury (25).
Contrary to all previous studies, Wen et al. demonstrated 
that total MSC EVs were more effective in the protection 
of bone marrow cells after irradiation than microvesicles 
or exosomes per se (58). These works underline the 
requirement of further studies providing data on the 
functional analysis of single EV fractions due to their 
possible different abilities.
Stem cell EVs and CKD
CKD is a complex pathology, which progressively occurs 
within time and differs for causes, severity and rate of 
progression in response to a number of possible inducers (7). 
The pre-clinical investigation of the efficacy of EVs in 
CKD therefore evaluated not only the different cell sources 
for EV isolation but also different doses, number and 
timing of administration (Table 2). Not less important is the 
starting point for treatment, that may be in the early stages 
to prevent progression of CKD, or when the disease is well 
established to revert chronic features. 
Several experimental models are available to mimic the 
broad range of pathologies included in the classification 
of human CKD. One of the main drivers of human CKD 
is diabetes. The early key features of DN are podocyte 
damage/loss and mesangial cell hypertrophy followed by an 
increase of extracellular matrix protein deposition (59). The 
first report of the beneficial effect of EVs in DN was very 
recently described by Jiang et al., in a rat model of diabetes 
inducted by streptozotocin injection. EVs isolated from 
MSCs derived from urine were administered weekly by 
intravenous injection of 100 μg of EVs for 12 weeks from 
the onset of diabetes. They were effective in prevention 
of DN progression (31). EVs induced a reduction of urine 
volume and urinary micro albumin excretion as well as a 
protection of podocyte and tubular epithelial cells from 
apoptosis. Analyses of EV content revealed the presence of 
protective factors such as transforming growth factor-β1, 
angiogenin and bone morphogenetic protein-7 (31). In 
addition, in both models of type 2 diabetes induced by high 
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fatty diet and type 1 diabetes caused by streptozotocin, 
the effect of stem cells per se (BM-MSCs) was compared 
with that of conditioned medium (CM) (29). MSC and 
MSC-CM therapies promoted a regeneration of injured 
kidney tissue suppressing cell infiltration and reducing 
interstitial fibrosis and glomerular alteration (29). They 
also demonstrated that key factors in the biological 
activity of cells were exosomes by their injection under 
the renal capsule in the streptozotocin DN model. One 
administration of exosomes generated a rapid improvement 
of renal morphology observed one or two weeks after EV 
treatment (29). Moreover, in a porcine model of metabolic 
syndrome and renal artery stenosis, a single intrarenal 
administration of EVs derived from autologous ASCs 
attenuated renal inflammation and improved medullary 
oxygenation and fibrosis four weeks post treatment. IL10 
was demonstrated as the main driver of the positive effect as 
vesicles with pre-silenced IL10 were ineffective (33).
Another in vivo model of CKD consists in a surgical 
five-sixth resection of the kidney tissue, also called 
remnant kidney model. It is characterized by a rapid 
decrease of nephron and glomerular filtration rate with 
glomerular hypertension that leads to glomerulosclerosis 
and fibrosis (60). He and co-workers showed that 
multiple injections of BM-MSC derived EVs prevented 
renal failure in the five-sixth model (28). The same others 
showed effect of BM-MSC derived EVs in a model of 
renal fibrosis induced by obstruction of the ureter (30). 
In tubular cells in vitro, EV treatment abrogated the 
morphological changes and the increase of the α-SMA 
secretion induced by transforming growth factor-β1 
stimulation (30).
In a similar model of five-sixth resection combined 
with L-NG-nitroarginine and 6% NaCl diet, multiple 
administrations of CM purified from human embryonic 
MSCs (twice daily intravenously for four consecutive days), 
after the development of CKD attenuated the deterioration 
of renal function. Six weeks after treatment, glomerular 
filtration rate and effective renal plasma flow were 
restored (32). On the contrary, exosomes isolated from 
the same cells resulted ineffective (32). This is the only 
paper, to our knowledge, that proposes the use of EVs in an 
established model of CKD. At variance, in the other models 
described here, EVs were administered immediately after 
damage in a preventive approach (12,17,18). 
In addition, several studies also indicate a beneficial 
effect of EVs in the progression toward fibrosis after AKI 
(12,13,23). In addition, in experimental models of renal IRI, 
EPC EVs limited the progression from AKI to CKD with a 
beneficial effect both on kidney tubular epithelial cells and 
on peritubular endothelial cells (23). 
Mechanism of action 
In recent years, many efforts were done, through RNA 
sequencing and proteomic analyses, to fully characterize RNA 
species (mRNAs or miRNAs) and proteins enriched in EVs 
and possibly involved in the biological activities observed (61). 
The recovery of AKI by EVs has been ascribed to several 
molecules that induced phenotypic changes in renal cells. 
MiRNAs are probable candidates for cell reprogramming 
toward a pro-regenerative phenotype (11). Indeed, many 
studies show that RNAs carried by EVs are the pivotal 
mechanism for their therapeutic function (62). The relevant 
role of miRNAs in the recovery of AKI was well demonstrated 
by non-specific miRNA depletion by Dicer or Drosha 
knockdown in stem cells (9,11,23). Drosha-knockdown cells 
generated EVs similar for surface molecule expression from 
those of native cells but ineffective in in vivo AKI model (11). 
To better elucidate the mechanism of action of MSC EVs and 
AKI, de Almeida et al. identified a group of miRNAs carried 
by mouse ASC EVs that targeted mRNAs associated with 
Wnt/TGF-β, fibrosis, and epithelial–mesenchymal transition 
signalling pathways (27). Authors demonstrated that miR-880, 
miR-141, miR-377, and miR-21 participated on regenerative 
process in vivo in an AKI model induced by cisplatin (27).
In addition, silencing of specific pro-angiogenic miRNAs 
(miRNA-126 and miRNA-296) in EPC EVs showed their 
relevant role in renal regeneration by abrogating EV 
efficacy in vivo after pro-angiogenic miRNAs depletion (23). 
These results indicate that miRNA cargo contributes to a 
reprogramming of renal cells toward regeneration.
The protein content of EVs was also extensively studied 
in the last years, especially that of EVs released by MSCs 
(63-65). They contained proteins that are connected to 
many biological aspects such as angiogenesis, extracellular 
matrix remodelling, regulation of inflammation, cell cycle 
and proliferation, cell migration and morphogenesis (63-65). 
Altogether, these results highlight the complex nature and 
the multiple effects of EVs that possibly may act in concert 
to exert their beneficial effects.
Renal biodistribution of EVs 
Several reports demonstrated that the stem cell biological 
activities do not require cell localization within damaged 
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organs (66). At variance, the transfer of EV cargo 
within damaged target cells is the first requirement for 
their biological function. EVs express several adhesion 
molecules involved in their up-take into renal tubular 
epithelium (10,67). Their ligand-receptor interaction seems 
fundamental also in vivo. In fact, pre-treatment of EVs with 
trypsin, that disrupts surface molecules, abolished EVs 
in vivo effect (10).
In physiological condition, intravenously injected EVs 
do not accumulate within kidney tissue not are cleared 
into urine, and spleen and liver are the main organs of 
localization (68). However, during damage, increase of 
permeability and cell loss favor EV tissue localization 
via peritubular capillaries or glomerular passage. By 
ex vivo immunofluorescence, MSC EVs and EPC EVs 
were localized within peritubular capillaries and tubules, 
immediately after their injection (one hour) in AKI models. 
The maximal accumulation was observed after six hours 
(10,12,23). Similar results were obtained by in vivo optical 
imaging technique: labelled MSC EVs using fluorescent 
lipophilic dyes localized within the renal tissue in an 
AKI model (9,68). The possibility to image and follow 
EV biodistribution in vivo may help to understand their 
regenerative potential. Different approaches of EV labelling 
such as fluorescent protein-based imaging, luciferase 
enzymatic activity and super paramagnetic iron oxide 
nanoparticles have not been tested yet in models of renal 
disease (68,69).
Stem cell EVs and kidney transplant
The ever-increasing demand for kidneys available for 
transplantation leads to take in account the kidney 
donation after circulatory death (DCD) as possible option 
to limit organ shortage. The use of hypothermic machine 
perfusion is currently used to ameliorate the viability of 
DCD kidneys. As MSCs injected in a renal transplant 
model are able to reduce IRI and to protect the graft (70), 
Gregorini et al. proposed a new application of MSCs: 
their use in pre-transplant graft perfusion. In this study, 
the pre-conditioning with MSCs or MSC-derived EVs 
in a rat model of DCD kidney was compared to standard 
perfusion solution in a hypothermic machine perfusion (71). 
DCD kidneys treated with MSC-derived EVs showed a 
significant lower global renal damage level than control 
kidneys. The observed effect of EVs was superior to MSCs. 
In fact, in MSC-perfused kidneys damage progression was 
only limited in the early stages, whereas in MSC-derived 
EV-perfused kidneys the development of ischemic damage 
was effectively stopped (71). Next step will consists in the 
characterization of factors contained in EVs that play an 
important role in the reduction of damage to promote 
the transplant of kidneys pre-conditioned with MSCs or 
MSC EVs. The application of these emerging therapies 
could be evaluated in organs not only from DCD donors 
but also from brain death donors included in the category 
“extended criteria donors” in accordance to Crystal City 
criteria (72). Moreover, an additional use of EVs in kidney 
transplantation could be envisaged by their systemic 
administration during transplant. This is supported by a 
recent report showing that EPC EVs i.v. injected at the 
moment of transplantation enhanced neoangiogenesis 
of human islets xenotransplanted in SCID mice, thus 
improving engraftment and function (73).
Conclusions
In conclusion, EVs appear a promising approach for renal 
regeneration (Figure 1). The beneficial effects of EVs, 
especially those derive from MSCs, are well established 
for the repair of AKI in several experimental models of 
renal injury. On the contrary, due to the complexity of 
the pathology, the application of EVs should be deeper 
investigated in CKD to better define therapeutic doses and 
the schedule of administration. Nevertheless, some evidence 
based on pre-clinical models, suggest the potential use of 
EVs also in a chronic damage. A promising new approach is 
the use of EVs for conditioning of kidneys before transplant. 
In addition, a further perspective for the application of EVs 
could be their engineering to potentiate their therapeutic 
cargo, by modification of surface molecules or by increasing 
active molecules (proteins or RNAs). 
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